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Summary Electrophoretic isoenzyme separation provides much more precise information than
measurement of alkaline phosphatases (AP). Use of this technique for 83 patients with Hodgkin's disease
revealed that the presence of the al fraction (al AP) was very significantly correlated with the stage of disease
extension (P<O.01) and above all with the presence of general symptoms (P<0.001). Repeat measurements
performed during patient follow-up demonstrated a close association between presence of al AP and existence
of progressive disease. While the mechanism of appearance of this abnormal al AP fraction is not linked to
Hodgkin-specific liver lesions, this test provides much more interesting data than classical measurement of
total alkaline phosphatases (TAP).
Although the Ann Arbor classification takes into
account an elevation in alkaline phosphatases and
abnormal liver function test results for the
diagnosis of liver involvement during Hodgkin's
disease, all of the large senes published (Bagley et
al., 1973; Belliveau et al., 1974; De Vita et al., 1971;
Glastein et al., 1969) emphasize the lack of
reliability of biological tests for such diagnoses.
Characterization of the isoenzymes of alkaline
phosphatase (AP) is one possible means of
rendering the data provided by such measurements
more precise. Our study was aimed at determining
whether the alpha 1 fraction of AP (al AP), also
called the 'fast liver' fraction, would provide more
valuable information. As in our previous work on
the metastases of solid tumours (Viot et al., 1983),
attention was centred on the presence of the al AP
fraction rather than on its concentration or its
percentage with respect to total AP in patients with
Hodgkin's disease.
Materials and methods
Population
Controls: sera from 101 adults and 30 children,
aged 0-2 years, were tested for the presence of al
AP.
Patients: the al AP fraction was searched for in
83 patients with Hodgkin's disease. There were 57
men, mean age 38 (range 7-90) and 26 women,
mean age 35 (8-79). Measurement were made
during the initial work-up prior to treatment,
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during a relapse, or during a complete, stable
remission. The cxl AP fraction was measured at the
time of disease diagnosis for a total of 59 of these
patients (40 men, 19 women, mean age 39 years),
who were staged as follows: 15 stage I, 25 stage II,
11 stage III, 8 stage IV. Histologic types included 6
type 1 disease, 30 type 2, 18 type 3 and 5 type 4.
Biological tests for determination of liver involve-
ment included: total bilirubin, alkaline phos-
phatases and isoenzymes, glutamate-pyruvate and
glutamate-oxaloacete transaminases, lactic dehydro-
genase and glutamate dehydrogenase. A technetium
scan was performed for 24 patients and ultrasound
scans for 47 patients. While obtained systematically
when the study was started, technetium scans were
later abandoned in favour of ultrasound. Axial CT
was performed for 13 patients. Liver biopsies were
obtained in 26 cases: 12 during laparotomy, 5
under laparoscopic guidance, 8 by fine needle
biopsy, and 1 at autopsy following sudden death.
The al AP fraction was also searched for in 22
patients during relapse. The biological tests used
were the same as those listed above. All 22 patients
were investigated by ultrasound; technetium scans
were obtained for only 4. Six biopsies were
obtained: 4 by fine needle biopsy, 1 by laparotomy,
and 1 at autopsy.
This fraction was also tested for in 12 patients in
complete remission for at least 6 months (status
confirmed since measurement; average follow-up 8
months).
Measurement techniques
Total alkaline phosphatase were measured with an
optimized technique at 25°C using a Centrifichem
400 unit. Paranitrophenyl phosphate was used as
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the substrate. The al AP fraction was measured
using a previously described technique (Viot et al.,
1983). In brief, following deposit by a micro-
applicator on a cellulose acetate strip, migration is
allowed to take place for 25min at pH 8.8 under a
potential difference of 150V. Phosphatase activity
is revealed by alpha-naphthol phosphate. The
various fractions (al AP, liver, bone, intestine) are
then quantified by densitometry at 610 nm (Figure 1).
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Figure 1 Electrophoretic separation
enzymes of alkaline phosphatase in a
high al AP fraction.
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Results
Results are summarized in Table I.
Controls
The cxl AP fraction was never detected in the sera
from the 101 adult controls or the 30 children.
Patients tested at the time ofdiagnosis
The al AP fraction was found in 16 of the 59
patients (27%) in the first perceptible disease phase;
it was observed in only 6 of the 40 stage I or II
patients (15%) but in 10 of the 19 stage III or IV
patients (53%). The correlation was significant
(P<0.01; x2 tests). It should be pointed out that
the 9 stage III or IV patients who did not present
this fraction included 6 who were classed as stage
III due to micronodular splenic involvement
discovered at laparotomy and 3 patients listed as
stage IV due to parenchymatous pulmonary
involvement without any sub-diaphragmatic lesions.
Inversely, the 4 positive al AP results for stage I or
II patients corresponded to a patient with
histological lesions of chronic alcoholism, which
can result in positive test findings (Viot et al.,
1979), a patient with large abdominal adenopathies
that compressed the hilar region and caused a
retention syndrome during which the al AP
fraction is always found (Viot et al., 1979), a
patient whose liver parenchyma showed isolated
steatosis and a patient with a microscopically
normal liver parenchyma. Elimination of the
alcoholic intoxication in the first patient and
reduction of the size of the lymph nodes by
chemotherapy in the second patient led to the
disappearance of the cxl AP fraction in both cases.
Table I Measurement of the al AP fraction and TAP in the various study groups
Presence of
Patients No. a] AP % TAP>200IU %
First perceptible stage 59 16 27 17 29
Stages I & II 40 6 p0o.o 15 9t,NS 22
Stages II &IV 19 10 53 89 42
TypeslI&2 36 6 P<005 17 7}P<0(05 19
Types 3 & 4 23 10 43 10 44
A (general symptoms present) 44 10 t S 23
B (general symptoms absent) 15 12 s 80 7 47
Sedimentation rate <50mmI-Ih 43 3 p<0.001 7
>50mmlP1h 16 11JP<69l
Relapses 22 20 90 12 54
Remissions 12 0 0 1 4
Controls: adults 101 0 0
children 30 0 0
NS=X2 not significant
al AP= alpha-l isoenzyme ofalkaline phosphatase
TAP=total alkaline phosphatases
A & B: general symptoms as defined in the textALKALINE PHOSPHATASE ISOENZYME DURING HODGKIN'S DISEASE 185
No statistically significant correlation was found
between the histological type and the presence of al
AP: this fraction was seen in 6 of the 36 type 1 or 2
patients (17%) and in 10 of the 23 type 3 or 4
patients (43%).
By contrast, if the absence (A) or presence (B) of
general symptoms (unexplained fever or night
sweats or weight loss of over 10% during the
previous 6 months) are considered, the al AP
fraction was detected for only 3 of the 44 patients
(7%) classed A versus 12 of the 15 patients (80%)
classed B. This correlation is statistically significant
(P<0.0001).
Analysis of the liver scans obtained for 22
patients and the liver sonograms obtained for 50
patients revealed no significant correlation between
the presence of axl AP and image abnormalities.
Comparison with total alkaline phosphatase The cxl
AP fraction was detected in 8 of the 46 patients
with a normal TAP level (<200IUl-1). Liver
biopsies were performed for two of these patients:
One had involvement by Hodgkin's disease and the
other had lesions due to chronic alcoholic hepatitis.
Conversely, this fraction was absent in 9 of the 13
patients with an elevated TAP concentration; these
cases included 4 young patients (8, 9, 17 and 19
years) plus 2 elderly patients (78, 80 years) with an
associated bone pathology. The increase in their
bone fraction was responsible for the elevated TAP
level in these patients.
In our series, the TAP did not discriminate
between stages I and II and stages II and IV, or
between groups with (A) or without (B) general
symptoms in a significant manner, whereas the al
AP fraction did (Table I).
Correlation with liver biopsy (26 patients) The al
AP fraction was detected in 3 of the 22 patients
whose biopsy did not show any involvement by
Hodgkin's disease. One of these patients was the
one with alcoholic hepatitis, another patients had
isolated steatosis, and the third patient had a normal
parenchyma despite marked biological pertubations
(TAP>307 IU-1).
The al AP fraction was present in the 3 patients
for whom biopsy revealed liver involvement by
Hodgkin's disease, even though one patient had a
normal TAP level.
Patients who relapsed
The al AP fraction was detected in 20 of the 22
measurements made for patients at relapse. This
frequency (90%) is markedly higher than the
elevation of the TAP to a pathological level which
occurred in 12 (54%) of these relapses. None of the
6 biopsies obtained for 6 of these patients with the
cxl AP freaction revealed any Hodgkin's disease
lesions; there was one instance of Kuppferian
siderosis.
Patients in remission
The al AP fraction was never detected in any of
the 12 patients in complete stable remission.
Correlation with disease evolution
Forty-two patients who did not have the cxl AP
fraction at the time of diagnosis achieved remission
(median duration 14 months). None of these
patients has relapsed, and the al AP fraction
appeared only temporarily in a patient with
hepatitis B.
Thirteen patients who initially exhibited the al
AP fraction have achieved remission, and have not
relapsed to date (median 17 months; range 7-36
months). The al AP disappeared during remission
in all cases and has never reappeared since.
Three patients who initially has the oxl AP
fraction did not achieve remission; the Lxl AP
fraction was present at all times during disease
evolution.
Two patients each relapsed three times, and were
under biological surveillance for a long period (48
and 64 months respectively). In these two patients,
the al AP fraction reappeared during each
perceptible disease stage and disappeared during
periods of remission. Autopsy performed for one of
these patients did not reveal any liver involvement
by Hodgkin's disease. Figure 2 illustrates the
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Figure 2 Evolution of the TAP level (-----) and the
al AP ( ) during successive relapses (R) in one
patient. The TAP did not rise during the second
relapse.186 A. THYSS et al.
evolution of the disease course for one of these
patients.
Discussion
Diagnosis of liver involvement by Hodgkin's
disease can only be proven by histology. Blind
percutaneous biopsy detects only around 30% of
such lesions. Multiple biopsies under laparoscopy
or by laparotomy considerably improve detection
rates (Bagley et al., 1973; De Vita et al., 1971;
Glastein et al., 1969; MacLeod & Stalker, 1962).
Hodgkin's lesions are generally diffuse from the
outset, or at least multifocal (Wraight & Symmers
1966). Such involvement is observed in 50% of
patients who die as a direct result of Hodgkin's
disease (Wraight & Symmers, 1966; Schener, 1973).
However, the lesions oberved can be the source of
debate, since even intense portal lymphocytic
infiltration is insufficient for diagnosis (Bagley et
al., 1973; Givler et al., 1971; Lukes, 1971).
Histological examination is thus indispensable; a
reliable, reproducible and non-traumatic method of
evaluating hepatic involvement by Hodgkin's
disease would also prove useful, especially during
patient follow-up. Clinical examination to detect
hepatomegaly (Bagley et al., 1973; Glastein et al.,
1969; Givler et al., 1971), liver scans (Givler et al.,
1971), ultrasonography (Caroll & Ta, 1980; Ginaldi
et al., 1980) and CT all give numerous false
positives or negatives. Biological tests such as the
bilirubin concentration, BSP retention, gamma-
glutamyl transpeptidase, oxaloacetic or glutamate-
pyruvate transaminases, or 5-nucleotidase (which is
useful in the case of malignant lymphomas) are not
commonly employed (Belliveau et al., 1974; Deeble
& Goldberg, 1980). Alkaline phosphatases appear
more useful: numerous studies have shown a clear
correlation between the AP concentration and the
disease stage (Belliveau et al., 1979; Deeble &
Goldberg, 1980; Aisenberg et al., 1970; Kaplan,
1980), whether or not there is any histologically
proven liver involvement. The actual significance of
elevation of AP levels remains unclear: an
unexplained and occasionally intense liver retention
syndrome has been observed for some time,
disappearing in some cases after supra-
diaphragmatic radiotherapy of stage I or II disease
(Perera et al., 1974).
Aisenberg et al. (1970) suggested that AP
isoenzyme separation could be used to eliminate the
false positives caused by the bone fraction in young
patients in whom this fraction is physiologically
elevated (Fishman & Ghosh, 1967). These authors,
however, used electrophoresis on a polyacrylamide
gel which does not separate the Lxl AP fraction,
which remains at the origin, despite the fact that ax
AP can represent 30 to 40% of AP activity in
certain pathologies (Viot et al., 1979). The origin of
the Lxl AP fraction remains uncertain, although it
appears to be the normal hepatic fraction
associated with a lipoprotein complex which might
be a fragment of a hepatocyte membrane (De Broe
& Wieme, 1975; De Broe et al., 1975). This would
be compatible with the presence of an AP activity
identical to al AP in bile (Viot et al., 1979), the
normal hepatocyte (Bagley et al., 1973; Viot et al.,
1979; Aisenberg et al., 1970), and neoplastic
hepatocytes (Burlina & Buggiardini, 1978).
The mechanism of appearance of the al AP
fraction is serum also remains unclear. It is always
present in cases of cytolysis or intense retention but
may also be present on an isolated basis. In a
previous study on the hepatic metastases of solid
tumours, we found that al AP was a significantly
more sensitive and often earlier biological indicator
than total AP or yGT; furthermore, this test does
not seem to be affected by the most common
chemotherapy regimens (Viot et al., 1983).
Significance ofal AP during Hodgkin's disease
In our series, the presence of al AP was correlated
with the degree of disease extension (P<0.01) and
with the presence of general signs (P<0.001). The
al AP fraction did not appear to be directly linked
to a specific liver pathology: it was found in the 3
patients with positive liver biopsies but was also
detected in 7 patients in a perceptible disease stage,
5 of whom had an apparently normal liver
parenchyma and 2 of whom presented nonspecific
liver lesions (1 alcoholic hepatitis, 1 siderosis).
However, the 5 patients with a normal liver
parenchyma were investigated only by fine needle
biopsy, which may have missed a Hodgkin's disease
lesion.
al AP measurement versus total alkaline
phosphatases
In our series, the presence of al AP was correlated
with an elevation of TAP (P<0.01) in patients in a
perceptible disease stage (first stage or relapse);
however, the value of al AP measurement appears
particularly marked in instances where there is a
discordance between these two parameters. Nine
patients had a TAP level over 200IUl-1 without
the al AP fraction, including 4 young patients (8,
9, 17, 19 years) and 2 elderly patients with an
associated bone pathology for whom the bone
fraction explained the high TAP level. al AP thus
appears especially interesting for biological liver
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Conversely, for 13 of our patients, the al AP
fraction was present although the TAP con-
centration was normal. One of these patients had
Hodgkin's disease lesions of the liver, suggesting
greater sensitivity for al AP measurements: this
point warrants confirmation in a larger population.
Two of these 13 patients had benign liver lesions.
The remaining 10 patients in this group constitute
a subgroup with a poor prognosis: they each had
from 1 to 4 relapses, 3 died of their disease, and
3 have progressive disease.
A correlation thus exists with the disease course
rather than with any specific hepatic pathology.
For the patients followed up on a regular basis by
monthly measurements in our study, the al AP
fraction was observed to appear at the time of
relapse. The al AP fraction does not seem to show
up any earlier that the other biological markers
available for the surveillance of Hodgkin's disease.
Conclusion
Measurement of the al AP fraction in the serum of
83 patients with Hodgkin's disease (59 at the time
of initial staging, 22 at relapse, 12 during complete
stable remission) revealed a statistically significant
correlation with the degree of disease extension and
the presence of general symptoms. During patient
surveillance, the appearance and disappearance of
this al AP fraction was closely linked with disease
evolution. Measurement of this fraction seems to
eliminate a certain number of the false positives
and negatives encountered with TAP measurements.
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